Literature DB >> 2917619

A norfloxacin dose finding study for selective decontamination of the digestive tract in pigs.

L A Van der Waaij1, O Messerschmidt, D Van der Waaij.   

Abstract

Five pigs were treated orally with norfloxacin for 5 consecutive days in two well-separated periods. This was done to determine the lowest dose required to free the pigs of Enterobacteriaceae. In the first period of the study, the animals were treated with 400 mg per day while in the second treatment 800 mg norfloxacin was given. Daily faecal culturing indicated that the faeces became free of Enterobacteriaceae in 3-5 days when treated with 400 mg/day, while all animals were found negative on culturing after 3 days of treatment with 800 mg/day. Investigation of the concentration of norfloxacin in the faeces revealed that a substantial fraction of the dose was either absorbed or inactivated by faecal substances. An in vitro study in faeces confirmed that a substantial part, some 75% of the dose, may have been inactivated by intestinal contents. This finding helps to explain the much lower concentration of 120 mg norfloxacin per kg of faeces in the pig in comparison with the almost tenfold higher concentration reported to develop in man during treatment with an identical dose.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2917619      PMCID: PMC2249321          DOI: 10.1017/s0950268800029721

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  12 in total

1.  Selective decontamination of the digestive tract by norfloxacin. A preliminary report.

Authors:  S S Pecquet; A O Andremont; C H Tancrède
Journal:  Prog Clin Biol Res       Date:  1985

2.  Pharmacokinetic studies of norfloxacin in laboratory animals.

Authors:  E C Gilfillan; B A Pelak; J A Bland; P F Malatesta; H H Gadebusch
Journal:  Chemotherapy       Date:  1984       Impact factor: 2.544

3.  Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers.

Authors:  R D Cofsky; L duBouchet; S H Landesman
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

4.  Biological inactivation by faeces of antimicrobial drugs applicable in selective decontamination of the digestive tract.

Authors:  E M Veringa; D van der Waaij
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

5.  Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract.

Authors:  D T Sleijfer; N H Mulder; H G de Vries-Hospers; V Fidler; H O Nieweg; D van der Waaij; H K van Saene
Journal:  Eur J Cancer       Date:  1980-06       Impact factor: 9.162

6.  Norfloxacin for prevention of bacterial infections in granulocytopenic patients.

Authors:  D J Winston; W G Ho; R E Champlin; J Karp; J Bartlett; R S Finley; J H Joshi; G Talbot; L Levitt; S Deresinski
Journal:  Am J Med       Date:  1987-06-26       Impact factor: 4.965

Review 7.  Review of the bioavailability and pharmacokinetics of oral norfloxacin.

Authors:  G E Stein
Journal:  Am J Med       Date:  1987-06-26       Impact factor: 4.965

8.  Effect of inoculum size on in vitro activity of norfloxacin against fecal anaerobic bacteria. Rationale for selective decontamination of the digestive tract.

Authors:  E J Goldstein; D M Citron; M L Corrado
Journal:  Am J Med       Date:  1987-06-26       Impact factor: 4.965

9.  Norfloxacin for selective decontamination: a study in human volunteers.

Authors:  H G De Vries-Hospers; G W Welling; D Van der Waaij
Journal:  Prog Clin Biol Res       Date:  1985

10.  Trimethoprim used for selective decontamination of the digestive tract in rats: possible route of excretion.

Authors:  A G Toorop-Bouma; D van der Waaij
Journal:  Scand J Infect Dis       Date:  1987
View more
  1 in total

1.  Use of norfloxacin to study colonization ability of Escherichia coli in in vivo and in vitro models of the porcine gut.

Authors:  E M Nielsen; J Schlundt
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.